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Abstract 
Background: The oncologic benefit of upfront re-excision of involved margins after breast-
conserving surgery in the context of current multimodal clinical management of breast cancer is 
unclear. The aim of the present study was to assess the 5-years locoregional recurrence (LRR)-free 
and distant metastases (DM)-free survival probabilities in patients not undergoing re-excision of 
positive margins after lumpectomy for breast cancer. 
Methods: A cohort of 104 patients with positive margins not undergoing re-excision was matched 
by propensity score with a cohort of 2,006 control patients with clear margins after breast-
conserving surgery, treated between 2008 and 2018. A multivariate survival analysis was performed 
accounting for all variables related to LRR and DM, including adjuvant treatments. 
Results: After adjusting for potential confounders, avoiding to re-excise a positive margin after 
lumpectomy had no effect on 5-years LRR-free survival probability (HR 0.98, 95%CI 0.36-2.67, 
p=0.96) or 5-years DM-free survival probability (HR 0.37, 95%CI 0.08-1.61, p=0.18). No 
correlation was found between occurrence of LRR and number of involved margins (HR 1.28, 
95%CI 0.10-12.4, Log-rank p=0.83), or extension of infiltrating disease (HR 1.21, 95%CI 0.20-
7.40, Log-rank p=0.83), but a trend toward higher LRR probability was found for invasive ductal 
(HR 6.92, 95%CI 0.7-68.8, Log-rank p=0.10) and invasive lobular cancer (HR 12.95, 95%CI 0.79-
213.6, Log-rank p=0.07) on positive margins. 
Conclusions: In the era of multimodal treatment of breast cancer and accurate strategies to reduce 
the probability of residual disease in the post-lumpectomy cavity, re-excision of positive margins 
might be omitted in selected patients with low-risk breast cancers. 
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Introduction 
Lumpectomy with a single line of normal cells between cancer and the resection limit is currently 
the standard of care of early breast cancer [1]. Indeed, the great majority of updated guidelines 
clearly state that “no ink on tumor” is the standard adequate margin and involved margins are 
considered inacceptable [2, 3]. Positive margins are related to a higher loco-regional recurrence 
(LRR) rate, because residual disease is likely to be left in the surrounding tissues [4-6]. But 
histopathology on re-excisions not always reveals residual disease [7-9]. Furthermore, up to 20-
50% of breast cancer patients treated by lumpectomy undergo re-excision of an involved margin 
and but re-excision is associated to heavier psychological burden for patients, delay of 
multidisciplinary case discussion and onset of adjuvant treatments, and increased costs [10, 11]. 
The benefit of upfront re-excision in all cases with involved margins in terms of LRR in current 
multimodal clinical treatment of breast cancer is not clear, since updated evidences are lacking [12]. 
The aim of the present study was to compare the 5-years LRR-free and distant metastases (DM)-
free survival probabilities between patients with involved margins not re-excised vs. patients with 
clear margins after breast-conserving surgery. 
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Material and methods 
Study population 
Patients were retrospectively collected from the prospectively-maintained database of the 
EUSOMA-accredited Breast Unit of ICS Maugeri Hospital from January 2008 to January 2018. 
Inclusion criteria were proven diagnosis of breast cancer, any size if suitable for lumpectomy and 
evaluation of margins status on final histopathology. Exclusion criteria were: benign disease, 
indication for total mastectomy, neoadjuvant treatment, distant metastases at diagnosis, or palliative 
surgery without curative intent. A total of 2,160 patients affected by breast cancer and treated by 
breast conserving-surgery were reviewed. 
 
Surgical procedure 
All patients underwent preoperative radio-guided occult lesion localization. Briefly, 15-25 MBq of 
99mTc-labelled human serum albumin nanocolloids (Nanocoll, GEHC, Italy) in 0.2 mL saline were 
injected by ultrasound guidance the day before surgery. A scintigraphy was performed to assess the 
adequacy of procedure. During surgery, lesion projection on breast skin was localized by a gamma 
probe (Bluetooth Neoprobe Gamma Detection System) to plan the incision. The excision was 
continuously guided by the gamma probe, to check the inclusion of the lesion within the specimen. 
After lesion resection, the gamma probe was used to assess possible residual signal in the cavity. In 
all cases, the sentinel lymph node biopsy was performed by radioisotope technique. All the 
procedures were performed by the same surgical equipe. 
 
Evaluation of margins and multidisciplinary management 
In all cases margins status was available on final pathology, and all patients were discussed in the 
weekly multidisciplinary meeting of our institution to plan the adjuvant treatments. The margins 
status was determined on all six planes of the surgical specimen. According to current guidelines, 
adequate margins were defined as “no ink on tumor” [2]. A focally positive margin was defined as 
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cancer invading for less than 4 mm in length the inked margin; in case of tumor involvement of 
more than 4 mm in length on inked margin, this was considered as extensively involved. In case of 
positive margins, a re-intervention was considered mandatory: a re-excision was proposed in case 
of extensive involvement of a single margin or multiple focally positive margins, while total 
mastectomy was preferred for multiple extensive margins or if a misdiagnosed multifocal disease 
was suggested on histopathology after lumpectomy. Patients who refused the proposal of re-
excision despite positive margins were the target population of the study.  
 
Study design and endpoints 
Patients were divided in two groups: those with negative margins at first surgery or undergoing a 
re-intervention after positive margins (control patients, CP) and those with positive margins who 
were not subjected to re-excision (not re-excised, NR). The two groups were compared in terms of 
1) 5-years LRR-free survival probability and 2) 5-years DM-free survival probability. LRR was 
defined as the occurrence of ipsilateral breast cancer or nodal disease at axillary, internal mammary 
and/or supraclavicular level, proven on core biopsy. DM was defined as the occurrence of distant 
lesions with computed tomography and positron emission tomography features suggestive of 
malignancy. We also evaluated: 1) cancer-related death rate, 2) impact of number of positive 
margins, extension and histology of infiltrating disease on LRR. Due to the non-random design of 
the study, a propensity score-matched analysis was performed matching NR and CP, to reduce bias 
resulting from possible confounders between the two groups. NR and CP were matched at 1:5 ratio 
according to the subsequent preoperative variables: age, histological type, pT and pN stages, 
grading and biomolecular subtype (Luminal A, Luminal B, HER2-positive and triple-negative). 
Propensity score matching was preferred given the presence of confounding variables which could 
affect the choice of treatment (re-excise or not re-excise), to account for this selection bias. 
However, since propensity score matching could decrease the available sample size, potentially 
under-powering the study, comparison between groups was also checked by re-analyzing the study 
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population through inverse probability weights (IPW) adjustment, thus including all 2,160 patients. 
A multivariate survival analysis was performed accounting for all variables related to LRR and DM, 
including adjuvant treatments. 
 
Statistical analysis 
Differences between NR and CP after propensity score-matched analysis were assessed to verify the 
heterogeneity of the study population. Variables were reported as means ± standard deviations or as 
absolute numbers and percentages. Categorical variables were compared using χ2 test or Fisher 
exact test as appropriate, while continuous variables were compared using Student’s T test or non-
parametric Wilcoxon test. To verify the adequacy of sample size to evaluate the end-points, the 
ideal sample size was calculated as for an equivalence study model. The null hypothesis was that re-
excising or not re-excising a positive margin would have resulted in different outcomes in terms of 
disease free-survival. Considering a global recurrence rate of about 10% both for invasive cancer 
and ductal carcinoma in situ (DCIS), and a hypothesized difference between groups of 10-12%, it 
would have been sufficient to include about 100 patients per group to achieve a study power of 90% 
with a confidence level equal to 0.05. Based on these considerations, sample size was considered 
adequate. NR and CP were compared by Cox proportional hazard regression model including 
variables significantly associated with the outcomes, included type of adjuvant treatment. The 5-
years LRR-free and DM-free survival probabilities were estimated by the Kaplan-Meier method. 
Statistical significance was set at p<0.05 (two tailed). Data analysis was performed using SAS 
software (v. 9.4, SAS Institute Inc., Cary, USA). 
 
 
 
 
 
7 
Results 
Margins status and distribution of baseline variables after propensity score-matching 
Of 2,160 patients reviewed, 2,006 cases (92.9%) had clear margins on final pathology after 
lumpectomy, while in 154 patients (7.1%) positive margins were found. Of the latter 154 patients, 
50 (2.3%) were re-excised while 104 (4.8%) refused re-intervention. Considering re-excised 
patients, in 18 cases (36.0%) residual disease was found on histopathology after re-intervention, 
while no evidence of further cancer was encountered in the remaining 32 cases (64.0%). After 
propensity score matching, a total of 624 patients were included for analysis of the endpoints: 104 
NR (16.7%) vs. 520 CP (83.3%). Distribution of baseline variables was balanced between groups, 
as reported in Table 1. Radiotherapy was offered to 89.4% of NR vs. 81.4% of CP (p=0.05). 
Radiotherapy was delivered with a conventional 3D conformal technique to the whole breast with 
two tangential fields, for a total dose of 45 Gy in 20 fractions plus a possible boost of 5 Gy in 4 
weekly fractions. Boost was delivered in 90.3% of CP vs. 95.7% of NR patients (p=0.11). 
Chemotherapy was administered respectively in 22.1% and 21.3% of cases (p=0.86). 
Chemotherapy regimen was based on anthracyclines with or without taxanes in 58.3% of NR vs. 
45.5% of CP, and trastuzumab was administered respectively in 38.9% and 45.5% of cases; in the 
remaining cases, other regimens (2.8% vs. 9.0%) were offered (p=0.49). Hormone therapy was 
received by 73.1% of NR and 77.9% of CP (p=0.29). 
 
Long-term outcomes and event-free survival probabilities between not re-excised vs. control 
patients 
Mean follow up after breast cancer surgery was 48.6 (±30.6) months in NR patients vs. 44.8 (±36.8) 
months in CP (p=0.09). LRR occurred in 4.8% of NR patients and in 5.6% of CP (p=0.75), while 
DM were observed respectively in 1.9% and 5.6% of cases (p=0.12). Of 34 LRR, 23 (67.6%) 
occurred as in-breast local disease, and 11 (32.4%) as ipsilateral axillary and/or supra-clavicular 
nodal recurrence. No difference was observed also in cancer-related death rates, being 3.9% both in 
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NR and CP (p=1.00). All these data are reported in Table 2. NR and CP showed comparable 5-years 
LRR-free survival probability curves, with a hazard ratio (HR) for not re-excising a positive margin 
equal to 0.90 (95%CI 0.35-2.35, Log-Rank test p=0.83), see Figure 1a. Also 5-years DM-free 
survival probabilities were similar between NR and CP (HR 0.33, 95%CI 0.08-1.38, Log-Rank test 
p=0.11), as showed in Figure 1b. After adjusting Kaplan-Meier survival analyses by IPW, not re-
excising a positive margin still had no impact on 5-years LRR-free (Log-Rank test p=0.94) or DM-
free (Log-Rank test p=0.14) survival probabilities, as showed in Supplementary Figures S1 and S2. 
 
Multivariate survival analysis of not re-excising positive margins on LRR-free and DM-free 
survival probabilities 
After adjusting for potential confounding variables by Cox regression model, avoiding to re-excise 
a positive margin after lumpectomy confirmed no effect on 5-years LRR-free survival probability, 
with an adjusted HR equal to 0.98 (95%CI 0.36-2.67, p=0.96). No variable resulted to be 
independently associated to LRR. Not re-excising positive margins had no impact also on 5-years 
DM-free survival probability (adjusted HR 0.37, 95%CI 0.08-1.61, p=0.18). Independent predictors 
of DM-free survival probability were nodal status (HR 0.22 for N1 vs. N2, 95%CI 0.07-0.72, 
p=0.013) and the need for adjuvant chemotherapy (HR 6.12, 95%CI 1.97-18.99, p=0.002). Cox 
multivariate analysis is reported on Table 3. 
 
Impact of number of positive margins, extension and histopathology of infiltrating disease on LRR 
In 79 NR patients (76.0%) 1 single involved margins was found on final pathology, and 25 cases 
(24.0%) had >1 positive margin. A focal involvement was encountered in 70 cases (67.3%), while 
extensive infiltration was observed in 34 patients (32.7%). No correlation was found between 
occurrence of LRR and number of involved margins (HR 1.28 for >1 vs. 1 involved margin, 95%CI 
0.10-12.4, Log-rank p=0.83), or extension of infiltrating disease (HR 1.21 for extensive vs. focal 
infiltration, 95%CI 0.20-7.40, Log-rank p=0.83). Histopathology on involved margins revealed 
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DCIS in 68 (65.4%) patients, ductal invasive cancer in 27 (26.0%) and lobular invasive cancer in 9 
(8.6%) cases. No correlation was observed with LRR, with HR equal to 6.92 for invasive ductal vs 
DCIS (95%CI 0.7-68.8, Log-rank p=0.10) and 12.95 for invasive lobular vs. DCIS (95%CI 0.79-
213.6, Log-rank p=0.07). 
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Discussion 
An accurate preoperative lesion localization and the adoption of current guidelines on the adequacy 
of surgical margin in breast-conserving surgery have greatly reduced the re-excision rate and related 
healthcare costs [10, 11]. Since several features of the proposed toolbox for reducing re-operations 
after breast cancer surgery are adopted in our institution, it is not surprising that only 2.3% of 
patients were re-excised to achieve adequate margins. Notably, in 4.8% of patients with involved 
margins a re-excision was refused. This is a major point of controversy, because currently no 
guideline accepts less than no ink on tumor for invasive cancer, with the only exception of Dutch 
guidelines which support the avoidance of re-intervention in case of focally positive margins [13].
 
 
It should be noted that the great majority of NR patients had pT1 (72.1%), node-negative (75.0%), 
Luminal A (56.0%) lesions, therefore a large proportion of these patients had a low-risk breast 
cancer. Interestingly, chemotherapy (22.1% vs. 21.3%, p=0.86) and hormone therapy (73.1% vs. 
77.9%, p=0.29) rates were comparable between NR patients and CP, therefore omission of re-
excision of positive margins was not associated to enhancement of adjuvant treatments. Conversely, 
a slight but not significant trend in a higher use of radiotherapy was evident in NR patients (89.4% 
vs. 81.4%, p=0.05), expectedly to minimize LRR occurrence. 
 
After controlling for baseline features by propensity score matching, omitting to re-excise a positive 
margin was not related to a higher LRR rate, being 4.8% vs. 5.6% in control group (p=0.75). Also, 
DM rates were similar (p=0.12). At multivariate analysis accounting also for post-operative 
treatments, included radiotherapy, still avoiding reoperation for positive margins had no effect on 
LRR (HR 0.98, p=0.96) or DM (HR 0.37, p=0.18). The absence of any effect on 5-years survival 
probabilities omitting to re-excise a positive margin is puzzling, but some explanations may be 
hypothesized. First, all patients underwent preoperative localization, therefore residual disease was 
unlikely to be left in post-lumpectomy cavity, as demonstrated by the fact that 64% of re-excised 
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patients had not residual disease on specimen after re-operation. Several other studies have showed 
that often residual cancer is not found on final pathology after re-excision for a positive margin [7-
9, 14, 15]. In other words, a margin could be incorrectly considered positive after handling of the 
specimen for histopathological analysis, since the pathologist might misunderstand its interpretation 
due to specimen shrinkage [16, 17]. Another point to be considered is the type of margin 
involvement. In the great majority of NR patients, a single (76.0%), focally positive (67.3%) margin 
involved by intraductal cancer (65.4%) was observed on histopathology. Therefore, the eventuality 
of a clinically significant residual disease after lumpectomy is unlikely, and radiotherapy together 
with adjuvant treatments could have been sufficient to control the disease at loco-regional level 
[18].
 
 
Due to the low event rate, the association between histopathology of cancer at inked margin, 
extension of involvement, number of involved margins and LRR could not be analyzed. However, a 
non-significant trend in increasing LRR after omitting re-excision was observed for invasive ductal 
(HR 6.92, p=0.10) and invasive lobular cancer (HR 12.95, p=0.07) compared to DCIS. 
 
Only few studies analyzing oncologic outcomes after not re-excising a positive margin after breast-
conserving surgery are available in recent literature [18-21]. Since Dutch breast cancer guidelines 
do not recommend re-excision for focally positive margins, Vos et al. published a study on 492 
patients who were not subjected to re-intervention. LRR rate was 2.9% vs. 1.1% in case of re-
excision, but the difference was not statistically significant (0.099), and no association was found 
with overall or disease-free survival [18]. Similarly, a study from the United States reported that in 
selected cases omitting re-excision of positive margins are not associated with increased LRR rates, 
particularly for anterior and posterior margins, if radiotherapy is administered [19]. Another study 
analyzing a large cohort proposed radiotherapy without re-excision as a viable option to control for 
LRR after positive margins on lumpectomy, in case of older patients with low-risk cancer [20]. 
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Furthermore, the effect of radiotherapy could be maximized by boost delivered at the positive 
margin [21]. A recent meta-analysis confirmed that positive margins after lumpectomy predict a 
higher LRR (OR 1.96, p<0.001)
 
[22], but it should be noted that most of reviewed evidences were 
published in another era of breast cancer treatment, when the definition of adequate margins and the 
availability of adjuvant treatments were quite different from current clinical practice [23].
 
 
Conclusions 
In the era of multimodal treatment of breast cancer and accurate strategies to reduce the probability 
of residual disease in the post-lumpectomy cavity after breast-conserving surgery, re-excision for 
positive margins might be omitted in selected patients with low-risk breast cancers. Since a single 
focally positive margin is encountered in the majority of cases with involved margins and 
considering the absence of residual disease in most re-excised patients, avoiding re-operation could 
be discussed in such cases. 
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Tables 
Table 1. Distribution of baseline variables after propensity score matching 
 
Cancer-free margins 
(n = 520) 
Not re-excised 
(n = 104) 
p-value 
Age at diagnosis (years) 63.3 (±12.6) 63.2 (±13.6) 0.79 
Histological Type 
DCIS 91 (17.5%) 20 (19.2%) 
0.34 Ductal invasive carcinoma 381 (73.3%) 70 (67.3%) 
Lobular invasive carcinoma 48 (9.2%) 14 (13.5%) 
Grading 
G1 51 (9.8%) 7 (6.7%) 
0.61 G2 315 (60.6%) 66 (63.5%) 
G3 154 (29.6%) 31 (29.8%) 
pT stage 
pT1a/pT1mic 22 (4.2%) 7 (6.7%) 
0.52 
pT1b 109 (21.0%) 22 (21.2%) 
pT1c 222 (42.7%) 46 (44.2%) 
pT2 76 (14.6%) 9 (8.7%) 
pTis 91 (17.5%) 20 (19.2%) 
pN stage 
pN0/pNmic 388 (74.6%) 78 (75.0%) 
0.72 pN1 92 (17.7%) 16 (15.4%) 
pN2-3 40 (7.7%) 10 (9.6%) 
Biomolecular subtype 
Luminal A 317 (70.0%) 62 (59.6%) 
0.10 
Luminal B 152 (29.2%) 27 (26.0%) 
HER2+ 9 (1.7%) 6 (5.8%) 
TNBC 42 (8.1%) 9 (8.6%) 
Hormone therapy 
No 115 (22.1%) 28 (26.9%) 
0.29 
Yes 405 (77.9%) 76 (73.1%) 
Chemotherapy 
No 409 (78.6%) 81 (77.9%) 
0.86 
Yes 111 (21.3%) 23 (22.1%) 
Radiation therapy 
17 
No 97 (18.6%) 11 (10.6%) 
0.05 
Yes 423 (81.4%) 93 (89.4%) 
Radiation boost    
No 41 (9.7%) 4 (4.3%) 0.11 
Yes 382 (90.3%) 89 (95.7%)  
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Table 2. Long-term outcomes between not re-excised vs. control patients 
 
Cancer-free margins 
(n = 520) 
Not re-excised 
(n = 104) 
p-value 
Mean follow up (months) 44.8 (±36.8) 48.6 (±30.6) 0.09 
Loco-regional recurrence 
No 491 (94.4%) 99 (95.2%) 
0.75 
Yes 29 (5.6%) 5 (4.8%) 
Type of loco-regional recurrence    
In-breast local recurrence 19 (65.5%) 4 (80.0%) - 
Axillary/Supra-clavicular nodal disease 10 (34.5%) 1 (20.0%)  
Distant metastases 
No 491 (94.4%) 102 (98.1%) 
0.12 
Yes 29 (5.6%) 2 (1.9%) 
Any first event 
No 462 (88.9%) 96 (92.3%) 
0.29 
Yes 58 (11.1%) 8 (7.7%) 
Cancer-related death 
No 500 (96.1%) 100 (96.1%) 
1.00 
Yes 20 (3.9%) 4 (3.9%) 
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Table 3. Multivariate analysis of clinical variables associated with loco-regional recurrence and 
distant metastases 
 Loco-regional recurrence Distant Metastases 
 
Hazard 
Ratio 
95% CI p-value 
Hazard 
Ratio 
95%CI p-value 
Age at diagnosis 1.03 (0.99-1.07) 0.08 1.03 (0.99-1.07) 0.12 
Margins       
Positive not re-excised vs. clear 0.98 (0.36-2.67) 0.96 0.37 (0.08-1.61) 0.18 
Histological type       
Invasive ductal vs. DCIS 2.09 (0.01-428.14) 0.79 1.18 (0.0-7,165.96) 0.97 
Invasive lobular vs. DCIS 2.77 (0.01-634.2) 0.71 2.20 (0.0-13,874.6) 0.86 
pT stage       
pT1 vs. pTis 1.10 (0.01-225.0) 0.92 1.35 (0.0-8,125.8) 0.95 
pT2-3 vs. pTis 1.33 (0.01-300.18) 0.92 2.36 (0.0-14,725.9) 0.85 
pN stage       
pN0 vs. pN2 1.28 (0.24-6.73) 0.77 0.37 (0.14-0.98) 0.046 
pN1 vs. pN2 0.72 (0.12-4.31) 0.72 0.22 (0.07-0.72) 0.013 
Grading       
G1 vs. G3 0.59 (0.13-2.64) 0.49 2.43 (0.46-12.9) 0.30 
G2 vs. G3 0.57 (0.21-1.58) 0.28 1.72 (0.71-4.17) 0.23 
Biomolecular subtype       
Luminal A vs. TNBC 0.63 (0.12-3.40) 0.59 0.65 (0.15-2.81) 0.56 
Luminal B vs. TNBC 0.65 (0.14-3.08) 0.58 1.10 (0.32-3.77) 0.88 
HER2+ vs. TNBC 0.34 (0.04-4.14) 0.43 NA* NA NA 
Chemotherapy       
Yes vs. no 0.52 (0.14-1.93) 0.33 6.12 (1.97-18.99) 0.002 
Hormone therapy       
Yes vs. no 0.51 (0.19-1.41) 0.20 0.50 (0.18-1.40) 0.19 
Radiation therapy       
Yes vs. no 0.48 (0.19-1.23) 0.13 1.07 (0.27-4.20) 0.92 
*NA: not available, due to lack of patients in one category. 
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Figure Captions 
 
Fig. 1 Survival probability curves of patients with positive margins not undergoing re-excision vs. 
patients with clear margins after lumpectomy. a) 5-years loco-regional recurrence-free survival 
probability; b) 5-years distant metastases-free survival probability. 
